Skip to content
The Nexus
DossierENTITY

Matt Kaeberlein

Coverage of Matt Kaeberlein in the Nexus archive.

Earliest in view: Jun 18 · 11:30 UTCMost recent: Jul 30 · 17:10 UTC
Co-mentioned in this coverage
Montanaplace1Montana’s Department of Health and Human Servicesorganization1Alliance for Longevity Initiativesorganization1Ken Bognerperson1Aaron Kesselheimperson1Niklas Anzingerperson1right-to-try legislationtopic1David Sinclairperson1Life Biosciencesorganization1cellular reprogrammingtopic1glaucomatopic1epigenetic reprogrammingtopic1National Institute on Aging's Division of Aging Biologyorganization1Felipe Sierraperson1
Recent coverage
  • HEALTHJul 30 · 17:10 UTCMIT TECHNOLOGY REVIEW
    Montana’s plan to become an experimental medical hub just pushed forward

    Montana has established a pathway for biotech companies to sell experimental drugs to consumers after preliminary testing, requiring a $12,500 application fee and approval by a review board. The law allows access to anyone with informed consent, not just terminal patients, and includes oversight by a board with doctors, scientists, and ethicists. Critics warn of risks from unproven treatments, while supporters emphasize rigorous oversight.

  • HEALTHJun 18 · 11:30 UTCAXIOS
    Longevity medicine's do-or-die moment

    The first human trial of an experimental gene therapy aims to test the safety of cellular reprogramming to rejuvenate aging cells, with initial focus on treating glaucoma. The trial, sponsored by Life Biosciences co-founded by David Sinclair, represents a critical step in validating the potential of epigenetic reprogramming to address age-related diseases.